Peptide Synthesis Market Grows on Back of Custom Services and API Demand
The global peptide synthesis market is poised for significant growth, driven by increasing demand for therapeutic peptides, rising adoption in pharmaceutical and biotechnological applications, and continued advancements in solid-phase peptide synthesis (SPPS) technology. As the pharmaceutical industry expands its focus on biologics and targeted therapies, peptides are gaining recognition for their high specificity, bioactivity, and lower toxicity profiles.
The global
peptide synthesis market was valued at USD 679.93 million in 2024. It is
expected to grow from USD 762.36 million in 2025 to USD 2,175.91 million by
2034, at a CAGR of 12.4% from 2025 to 2034.
Market
Overview
Peptide
synthesis refers to the chemical or enzymatic production of peptides—short
chains of amino acids that serve critical biological functions. The two most
common synthesis methods are solid-phase peptide synthesis (SPPS) and
liquid-phase synthesis, with SPPS being the most widely used due to its speed,
efficiency, and scalability. Peptides serve a diverse array of roles in
therapeutics, diagnostics, and research, ranging from metabolic disorders and
cancer to infectious diseases.
The
market encompasses:
- Research-grade
peptides – used
in laboratories for academic and industrial R&D
- Good
Manufacturing Practice (GMP) grade peptides – for preclinical and clinical
drug development
- Peptide
Active Pharmaceutical Ingredients (peptide APIs) – for commercial pharmaceutical
manufacturing
Peptide
drugs such as insulin, glucagon-like peptide-1 (GLP-1) analogs, and various
hormone-based treatments underscore the increasing relevance of peptides in
modern medicine.
Key
Market Growth Drivers
1.
Rising Demand for Therapeutic Peptides
The
rising prevalence of chronic diseases such as cancer, cardiovascular
conditions, and metabolic disorders has driven increased demand for therapeutic
peptides. These molecules exhibit excellent efficacy and safety profiles,
making them ideal candidates for targeted therapies. Over 80 peptide-based
drugs are currently approved globally, with more than 150 in clinical trials.
2.
Technological Advancements in SPPS
Solid-phase
peptide synthesis has
seen remarkable improvements in recent years, including better resins, linkers,
and automation. These advancements enable faster production of long and complex
peptide chains with higher purity and yield, making SPPS the gold standard in
both research and industrial settings.
3.
Expanding Applications in Diagnostics and Vaccines
Beyond
therapeutics, peptides are being increasingly used in diagnostic assays,
especially for infectious diseases, autoimmune conditions, and cancer markers.
Furthermore, the role of peptides in vaccine development (such as peptide-based
COVID-19 vaccines) has garnered interest, leading to greater R&D
investment.
4.
Surge in Custom Peptide Synthesis Services
Pharmaceutical
companies, academic institutions, and research labs are increasingly
outsourcing peptide production to specialized firms offering custom peptide
synthesis. These services enable fast turnaround times, high precision, and
cost efficiency, thereby accelerating drug discovery and biomarker validation.
5.
Favorable Regulatory and Investment Landscape
Governmental
support for peptide drug development, coupled with significant VC and pharma
investments in peptide-based startups and biotechs, is creating a fertile
ground for growth. Regulatory frameworks are also evolving to accommodate
peptide-based therapies more effectively.
Market
Challenges
1.
High Production Costs
Peptide
synthesis, particularly of long or complex sequences, involves high material
costs and sophisticated technology. This limits scalability and affordability,
especially for startups and academic institutions with limited budgets.
2.
Purification and Stability Issues
Peptides
are prone to degradation and require stringent storage and purification
conditions. Ensuring high purity and shelf-stability is a major technical
challenge that can hinder commercialization.
3.
Manufacturing Complexity of Peptide APIs
Producing
peptide APIs at GMP standards for large-scale pharmaceutical use demands
specialized infrastructure and adherence to strict regulatory protocols,
creating barriers for new entrants and increasing production timelines.
4.
Limited Oral Bioavailability
Despite
advances in peptide delivery systems, most peptide drugs require parenteral
administration due to poor oral bioavailability. Research is ongoing, but this
limitation continues to hinder broader adoption in oral formulations.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞
@ https://www.polarismarketresearch.com/industry-analysis/peptide-synthesis-market
Regional
Analysis
North
America
North
America dominates the global peptide synthesis market, accounting for more than
40% of total revenue. The U.S. leads due to strong pharmaceutical R&D, high
prevalence of chronic diseases, and a robust pipeline of therapeutic
peptides. Major biotech clusters in Boston and San Francisco contribute
significantly to innovation and commercial growth.
Europe
Europe
holds the second-largest market share, with strong academic research
infrastructure and increasing investment in biologics. Germany, the U.K., and
France are major contributors, supported by favorable funding from the European
Commission for peptide-based therapeutics and diagnostics.
Asia-Pacific
The
Asia-Pacific region is expected to witness the fastest growth during the
forecast period. Countries such as China, India, Japan, and South Korea are
ramping up peptide manufacturing capacity and investing in R&D. Low-cost
manufacturing, increasing healthcare expenditure, and expansion of CDMO
services are key growth drivers in this region.
Latin
America, Middle East & Africa
These
emerging markets are gradually entering the peptide space, supported by
improving healthcare infrastructure and growing biotech ecosystems. Brazil,
South Africa, and UAE show early signs of growth, particularly in research
peptide demand and vaccine development collaborations.
Key
Companies in the Peptide Synthesis Market
The
global peptide synthesis market is moderately consolidated, with several key
players offering a wide range of custom peptide synthesis, catalog
peptides, and peptide APIs. Mergers, acquisitions, and capacity
expansions are common strategies used to gain competitive advantages.
Leading
Companies:
- Bachem
Holding AG
A Swiss-based leader specializing in GMP-grade peptides and APIs, with strong global distribution networks. - PolyPeptide
Group
Offers both therapeutic peptide manufacturing and custom synthesis services with facilities across Europe and the U.S. - GenScript
Biotech Corporation
A major player in custom peptide synthesis, particularly for research applications, with growing investments in biologics. - Thermo
Fisher Scientific
Offers high-purity peptides and peptide synthesis reagents through its research divisions. - Merck
KGaA (Sigma-Aldrich)
Known for its robust peptide catalog, synthesis reagents, and automated SPPS systems. - CordenPharma
Specializes in large-scale peptide API production and GMP-compliant peptide manufacturing services. - Creative
Peptides
Offers a wide range of catalog peptides, custom synthesis, and conjugation services for both research and clinical purposes.
Recent
Developments
- Bachem expanded its GMP production
capabilities in Switzerland and the U.S. to meet rising demand for
therapeutic peptides.
- PolyPeptide
Group announced
a strategic collaboration with biotech startups to co-develop
peptide-based oncology therapies.
- GenScript launched new peptide libraries
tailored for vaccine and diagnostic development.
- Thermo
Fisher
introduced enhanced SPPS automation systems to increase throughput and
reduce time-to-market for peptide products.
Future
Outlook and Trends
The
peptide synthesis market is set to evolve with several transformative trends:
- Increased
use of AI and machine learning in peptide sequence design and predictive
synthesis
- Development
of oral peptide delivery platforms to overcome bioavailability challenges
- Green
chemistry approaches to reduce waste and improve sustainability in SPPS
- Rise
of personalized peptide vaccines in oncology and infectious disease
management
- Growing
demand for peptide APIs in biosimilar and generic drug production
Conclusion
The
global
peptide synthesis market stands at the intersection of pharmaceutical
innovation, biologic advancement, and increasing demand for precision medicine.
As the landscape shifts toward more targeted and effective therapeutics, custom
peptide synthesis, efficient solid-phase peptide synthesis, and
scalable peptide API manufacturing will remain crucial pillars for
future growth. Overcoming cost and delivery challenges will unlock the next
chapter of peptide-based healthcare solutions.
More
Trending Latest Reports By Polaris Market Research:
Ddos Protection And Mitigation
Security Market
Comments
Post a Comment